PFAS Health Risks: What Peer-Reviewed Science Means for Water Treatment Despite EPA Rollback

For water managers, the 2026 EPA rollback creates a significant liability gap: federal requirements are shrinking, but the liability linked to peer-reviewed health risks is expanding.

Drawing from a 2021 comprehensive toxicology review published in Environmental Toxicology and Chemistry (Fenton et al., 2021), this article bridges laboratory science to operational decisions. The research reveals health risks across the entire PFAS family that extend far beyond the two compounds EPA's narrowed 2026 rule still regulates, validating the need for treatment systems that protect communities regardless of federal policy shifts.

Why PFAS Health Effects Drive Treatment Urgency

Per- and polyfluoroalkyl substances (PFAS) aren't just another contaminant. Their unique chemistry (the same carbon-fluorine bonds that made them valuable in industrial applications) makes them extraordinarily persistent in both the environment and the human body.

According to CDC surveys, most people in the United States have been exposed to some PFAS. While many exposures are relatively low, concentrated sources can lead to significant accumulation over time. The reason? Many PFAS break down very slowly and bioaccumulate in people, animals, and the environment.

What the Peer-Reviewed Science Shows

A comprehensive 2021 review published in Environmental Toxicology and Chemistry analyzed hundreds of studies on PFAS toxicity and human health impacts. The data highlights critical vulnerabilities in current filtration strategies across multiple body systems:

Immune System Suppression

One of the most well-documented effects involves immune function. The Fenton et al. (2021) review analyzed epidemiological studies showing:

• Reduced vaccine effectiveness: Research by Grandjean and colleagues found that a doubling of PFOS in maternal serum was associated with a 39% reduction (p < 0.001) in diphtheria antibody concentration in children at age 5 years
• Increased infection risk: A pregnancy cohort study prospectively detected increased risk of airway and throat infections and diarrhea in children through age 10, correlated with cord-blood PFAS measurements
• Immune response impairment: The U.S. National Toxicology Program (2016) concluded that PFOA and PFOS are "presumed to be immune hazards to humans" based on high-level evidence for antibody suppression

The review emphasized that immunotoxicity should be considered among the most sensitive human PFAS toxicity endpoints. This means immune effects may occur at lower exposure levels than other health impacts.

Liver and Metabolic Effects

PFAS accumulate primarily in the liver, leading to measurable impacts:

• Elevated liver enzymes: Population studies demonstrate significant associations between long-chain PFAS exposure and higher liver enzyme levels in adults and adolescents
• Lipid metabolism disruption: Experimental and human data show PFAS interfere with bile acid metabolism, fatty acid transport, and cholesterol regulation
• Non-alcoholic fatty liver disease (NAFLD): Emerging evidence links PFAS to steatosis (fatty liver) through multiple metabolic pathways

Dyslipidemia (abnormal cholesterol levels) represents one of the strongest and most consistent metabolic outcomes across studies, with effects observed even at background exposure levels.

Kidney Function and Uric Acid

The kidneys play a dual role: they're both affected by PFAS and responsible for their excretion.

• Diminished kidney function: Longitudinal studies suggest PFAS exposure likely causes reduced glomerular filtration
• Elevated uric acid: Consistently associated with PFAS exposure in adults and children, a biomarker for increased renal disease risk
• Kidney cancer: Preliminary data from heavily exposed populations in Italy suggest significantly increased kidney cancer mortality

Thyroid Disruption

PFAS interfere with thyroid hormone regulation through multiple mechanisms:

• Binding to thyroid hormone carrier proteins (transthyretin, thyroxine-binding globulin)
• Interfering with thyroid peroxidase (TPO) enzyme activity
• Altering TSH levels in newborns and pregnant women

Women in the highest quartile of PFOA exposure showed more than double the odds of clinical hypothyroid disease compared to those with lower exposure.

Reproductive and Developmental Effects

The research documented multiple reproductive impacts:

• Reduced fertility: Time-to-pregnancy studies found associations with decreased fecundity, particularly with PFOS exposure
• Birth weight effects: Meta-analyses provide evidence of associations between PFOA exposure and reduced birth weight
• Pregnancy complications: The C8 Science Panel concluded PFOA is probably linked to pregnancy-induced hypertension and preeclampsia
• Developmental immunotoxicity: 22 of 24 reviewed studies suggest developmental and childhood immunomodulatory effects

From a public health standpoint, the most significant risk factor is transplacental and lactational transfer: PFAS cross the placenta and enter breast milk, meaning infants can have higher serum concentrations than their mothers due to smaller body mass and blood volume.

The Gap: EPA's Regulatory Position vs. Scientific Consensus

EPA's 2026 drinking water rule narrows federal oversight to just PFOA and PFOS (down from the Biden administration's 2024 six-compound rule). The following table compares regulatory coverage against peer-reviewed health evidence from Fenton et al. (2021):

Regulatory Context: EPA's 2026 rule reduces coverage from six PFAS to just two (PFOA and PFOS), while delaying the compliance deadline from 2029 to 2031. Replacement compounds like GenX show similar toxicity profiles to legacy PFAS but remain unregulated at the federal level.

Vulnerable Populations Require Special Consideration

The Fenton et al. (2021) review and epidemiological research emphasize that certain groups face higher risks:

Children

• Drink more water, eat more food, and breathe more air per pound of body weight than adults
• Still developing, potentially more sensitive to chemical effects
• Higher exposure through floor crawling, hand-to-mouth behavior with contaminated household items
• May be exposed in utero and through breast milk

Pregnant and Lactating Women

• Drink more water per pound of body weight than average
• Transfer PFAS to developing fetuses across the placenta
• Pass PFAS through breast milk (though current science suggests breastfeeding benefits still outweigh risks)

Industrial and Firefighting Workers

• Direct occupational exposure through chemical manufacturing, processing, or AFFF firefighting foam
• Often experience higher cumulative exposures than the general population

Communities Near Contamination Sources

• Living near PFAS-producing facilities, military bases with AFFF use, or certain waste sites
• Potential for long-term elevated exposure through drinking water and environmental pathways

What This Means for Water Treatment Decisions

Understanding the health science isn't academic. It directly informs treatment strategy:

1. Multi-Barrier Approaches Are Justified

Given the wide range of health effects across multiple organ systems documented in peer-reviewed research, comprehensive treatment that addresses the full spectrum of PFAS (not just the two compounds EPA's 2026 rule covers) becomes critical. The immunotoxicity data alone, with 39% reductions in vaccine response from prenatal PFOS exposure, underscores why treatment can't wait for regulatory limits that may never arrive.

2. Vulnerable Population Analysis Should Drive Urgency

Systems serving schools, hospitals, or communities with known exposure sources should prioritize PFAS assessment and treatment. The developmental and reproductive health data make this a matter of intergenerational health protection.

3. Treatment Media Selection Must Consider PFAS Diversity

Short-chain PFAS replacements (like GenX and ADONA) appear in the Fenton et al. (2021) review to have similar toxicity profiles to legacy compounds. Treatment systems need to address both legacy and emerging PFAS, not just the two compounds EPA's 2026 rule regulates.

4. Monitoring Should Reflect Current Science

The kidney function research cited in the review showing non-monotonic dose-response relationships (inverted U-shaped curves) suggests that understanding baseline exposure and vulnerable subpopulations matters as much as meeting numerical standards, even when those standards only cover two of thousands of PFAS compounds.

5. Documentation Supports Risk Communication

When communities ask "why does this matter?" or "why spend money on treatment when EPA rolled back the rule?", the answer isn't regulatory compliance. It's science. The peer-reviewed evidence documented in Fenton et al. (2021) of 39% immune suppression, developmental effects, and cancer risk provides the foundation for protecting public health regardless of shifting federal policy.

Operationalizing the Science: 2026 Strategy for Water Managers

The 2026 regulatory rollback shifts the burden from federal compliance to science-based risk management. For water system operators and facility managers, the Fenton et al. (2021) evidence base supports three immediate action items:

Audit for Total PFAS, Not Just Regulated Pairs

Deploy EPA Method 1633 to quantify the full PFAS profile, including GenX, PFBS, PFHxS, and PFNA that EPA's 2026 rule no longer covers. The Fenton review documents immunotoxicity and liver effects across these compounds at concentrations well below where legacy PFOA/PFOS trigger regulatory action. Baseline data now protects against future liability as state-level regulations continue to evolve independently of federal rules.

Future-Proof Your Filtration Media Selection

Opt for properly specified GAC for liquid-phase applications or PFAS-selective ion exchange resins designed for short-chain molecule capture (C4-C6 perfluoroalkyl chains). GenX and other "replacement" PFAS show similar health profiles to legacy compounds but require media with smaller pore structures and higher surface area. Selecting treatment media designed specifically for the full PFAS spectrum provides coverage regardless of which compounds EPA regulates in future rule revisions.

Prioritize Vulnerable Population Service Areas

Identify schools, hospitals, and maternal health facilities within your service territory. The 39% reduction in vaccine response and transplacental transfer data create elevated liability exposure for systems serving pregnant women and children under age 5. Risk-based prioritization using health science (rather than waiting for regulatory triggers) provides defensible documentation when community concerns arise or tort litigation targets water providers.

Bottom Line: EPA now regulates only 2 PFAS compounds, but science documents health risks from dozens more. Treatment systems addressing the full PFAS family, not just what EPA mandates, protect your community's health and shield your organization from future legal exposure.